NCT05103891View on ClinicalTrials.gov

Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

PHASE1UnknownINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

September 3, 2021

Primary Completion Date

November 29, 2021

Study Completion Date

November 29, 2021

Conditions

MelanomaBRAF V600 MutationUnresectable MelanomaMetastatic Melanoma

Interventions

DRUG

Binimetinib Oral Tablet

two-period, crossover study

Trial Locations (1)

35000

Biotrial, Rennes

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Biotrial

INDUSTRY

lead

Pierre Fabre Medicament

INDUSTRY

NCT05103891 - Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations | Biotech Hunter | Biotech Hunter